SUNNYVALE, California,
April 5, 2017 /PRNewswire/ --
Partnership Creates Strategic
Alliance for Clinical Education and Training
in Robotic Radiosurgery
Accuray Incorporated (NASDAQ: ARAY) announced today the signing
of a three-year Collaboration and Support Agreement with the N.N.
Burdenko National Scientific and Practical Center for Neurosurgery
in Moscow, Russia. The
collaboration is designed to expand education and training
opportunities for medical physicists using the CyberKnife® System
to treat conditions within the brain and spine. The institute is
one of the world's largest neurosurgical clinics and has a long and
successful history of treating intracranial and spinal
indications.
(Logo:
http://photos.prnewswire.com/prnh/20151126/291246LOGO)
(Photo:
http://photos.prnewswire.com/prnh/20151126/291247)
The agreement, which establishes a collaborative relationship
between Accuray and the Institute, will enable physicists from
Russia to receive peer-to-peer
training from the Burdenko team on the most current CyberKnife
System treatment planning and quality control techniques, and
treatment protocols for intracranial, spine, and other extracranial
cases. Attendees will also have the opportunity to observe patient
treatments.
"We are very pleased to collaborate with the renowned Burdenko
Center on the training of both experienced and new medical
physicists. We believe the CyberKnife System offers distinct
advantages in the treatment of neurological conditions and are
committed to working with the local Burdenko team to ensure our
customers will benefit from the System's unique functionalities,"
said Matthias Franz, EIMEA General
Manager and VP Commercial Operations at Accuray.
Established 84 years ago, the N.N. Burdenko National Scientific
and Practical Center for Neurosurgery has built strong clinical and
scientific traditions, enabling its medical team to develop
expertise in the diagnosis and treatment of neurological
conditions. Since its founding, the institute has been a reference
center for the treatment of patients with diseases of the central
and peripheral nervous system, not only in Russia, but in all former states of the Soviet
Republic.
The Department of Stereotactic Radiotherapy and Radiosurgery of
the N.N. Burdenko National Scientific and Practical Center for
Neurosurgery is equipped with modern radiosurgical and radiation
oncology technology including the CyberKnife System, which was the
first of its kind in Russia when
installed in 2009. Recently upgraded, the CyberKnife System
provides better image guidance and tracking capabilities as well as
a more efficient workflow, enabling the center to treat more
patients per day. The technology has been used to treat more than
4,500 patients, with an average of 15 patients per day.
"We chose the CyberKnife System because it enables us to deliver
both radiosurgery and hypofractionated treatments, providing
significant benefits for patients with a variety of indications
including spinal and intracranial lesions and in some cases,
metastatic lung, liver, and bone cancer," said Professor
Andrey Golanov, Head of the
Stereotactic Radiotherapy and Radiosurgery Department, N.N.
Burdenko National Scientific and Practical Center for Neurosurgery.
"We are launching the training program to help other physicians and
physicists optimize their use of the System. The Accuray - Burdenko
agreement will enable us to provide our colleagues from other
centers with training which will help them gain an understanding of
what is required to support a successful CyberKnife System program
at their center."
The CyberKnife System delivers radiosurgery and stereotactic
body radiation therapy (SBRT), enabling precise, high quality dose
distributions to be confidently delivered to the patient with
extreme accuracy over a minimum number of treatments, reducing side
effects and preserving patients' quality of life. It is the only
System capable of tracking and automatically correcting for target
motion in real time, even while the tumor moves. The System offers
a non-invasive treatment option for precisely treating lesions of
different sizes and locations, including tumors located near
critical structures.
About Accuray
Accuray Incorporated (NASDAQ: ARAY) is a radiation oncology
company that develops, manufactures, and sells precise, innovative
tumor treatment solutions that set the standard of care with the
aim of helping patients live longer, better lives. The company's
leading-edge technologies deliver the full range of radiation
therapy and radiosurgery treatments. For more information, please
visit http://www.accuray.com .
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, market acceptance of our new technologies,
patient outcomes and Accuray's leadership position in radiation
oncology innovation and technologies. Forward-looking statements
are subject to risks and uncertainties that could cause actual
results to differ materially from expectations, including but not
limited to the risks detailed from time to time under the heading
"Risk Factors" in the company's report on Form 10-K, filed on
August 24, 2016, the company's
reports on Form 10-Q, filed on November 1,
2016 and February 3, 2017, and
as updated periodically with the company's other filings with the
SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to
Accuray at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.